Stage 3 Mesothelioma
Executive Summary: Stage 3 mesothelioma represents an advanced but potentially treatable form of malignant pleural mesothelioma in which the tumor has invaded nearby structures or spread to regional lymph nodes but has not metastasized to distant organs. Under the TNM 8th edition staging system, Stage III is divided into Stage IIIA (locally advanced but potentially resectable disease) and Stage IIIB (technically unresectable local invasion). National Cancer Database (NCDB) data show that Stage III patients receiving chemotherapy have a median overall survival of approximately 15.5 months, while those receiving surgery plus chemotherapy may achieve a median survival approaching 18.9 months.[1] The 2020 FDA approval of nivolumab plus ipilimumab (CheckMate 743 trial) transformed the treatment landscape, with the combination achieving a median overall survival of 18.1 months across all stages and a 5-year survival rate of 14% versus 6% for chemotherapy alone.[2] Prognosis varies substantially based on cell type, performance status, and substage — epithelioid Stage IIIA patients with good performance status have meaningfully better outcomes than sarcomatoid Stage IIIB patients. Patients diagnosed with Stage 3 mesothelioma should seek evaluation at a high-volume treatment center where multidisciplinary teams can offer the full range of treatment options, including clinical trials of emerging therapies.
| Key Facts About Stage 3 Mesothelioma | |
|---|---|
|
|
What Is Stage 3 Mesothelioma?
Stage 3 mesothelioma is an advanced form of malignant pleural mesothelioma (MPM) in which the cancer has grown into nearby tissues or spread to regional lymph nodes but has not metastasized to distant organs. Under the International Association for the Study of Lung Cancer (IASLC) TNM 8th edition staging system — the current worldwide standard adopted in 2018 — Stage III is subdivided into two categories based on the extent of local invasion and nodal involvement:[3]
How Is Stage IIIA Defined?
Stage IIIA encompasses tumors that are locally advanced but potentially amenable to surgical resection in carefully selected patients:[3]
- T3 N0 M0 — Tumor invades endothoracic fascia, mediastinal fat, a solitary chest wall focus, or non-transmural pericardium, with no lymph node involvement
- T1–3 N1 M0 — Any T1 through T3 tumor with metastasis to ipsilateral (same-side) bronchopulmonary or hilar lymph nodes
- T1–3 N2 M0 — Any T1 through T3 tumor with metastasis to ipsilateral mediastinal lymph nodes including the internal mammary chain or peridiaphragmatic nodes
How Is Stage IIIB Defined?
Stage IIIB designates technically unresectable local disease:[3]
- T4 any N M0 — Tumor invades the chest wall diffusely (multifocal invasion), peritoneum via transdiaphragmatic extension, contralateral pleura, mediastinal organs (esophagus, trachea, heart, great vessels), brachial plexus, or spine — regardless of lymph node status
How Does Stage 3 Differ From Stage 2 and Stage 4?
Stage II mesothelioma involves tumor that is still relatively confined, typically T2 (tumor involving all ipsilateral pleural surfaces including fissures) with no nodal disease. Stage 3 marks the transition to either locally advanced invasion (T3) or regional lymph node spread (N1–N2). Stage IV mesothelioma indicates either distant metastasis (M1) or such extensive local disease that it has spread beyond the ipsilateral hemithorax.[3]
The IASLC Mesothelioma Staging Project, analyzing data from 3,101 patients across 15 centers, found that the hazard ratio for death in Stage III/IV compared to Stage I/II disease was 1.49 (95% confidence interval 1.18–1.89; p=0.0010) — confirming that stage remains an independent prognostic factor even after adjusting for cell type, age, sex, and performance status.[5]
What Is Changing With the TNM 9th Edition?
The proposed TNM 9th edition (2025), based on 3,598 patients from 29 centers across 4 continents, introduces a quantitative measurement called Psum — the sum of maximum pleural thickness measurements at three axial CT levels. This replaces several 8th edition T descriptors that proved unreliable on imaging. Under the 9th edition proposal, Stage IIIA is redefined as T2N1M0, T3N0–1M0, or T1–3N2M0, while Stage IIIB remains T4 any N M0. Notably, the 9th edition reclassifies some patients previously staged as IIIA under the 8th edition, which may affect interpretation of historical survival data.[9]
Important: When evaluating survival statistics for Stage 3 mesothelioma, it is essential to know which staging edition was used. Studies using the TNM 7th edition (before 2018) may classify different patient populations as "Stage III" than studies using the 8th or 9th editions. For a comprehensive overview of how mesothelioma staging has evolved, see Mesothelioma_Diagnosis_and_Staging.
What Are the Survival Statistics for Stage 3 Mesothelioma?
Stage 3 mesothelioma carries an intermediate prognosis between Stage II and Stage IV disease. Survival varies substantially depending on treatment modality, cell type, substage, and performance status.
What Do the National Cancer Database Numbers Show?
The most comprehensive Stage III survival data come from the NCDB analysis by Bou-Samra et al. (2023), which examined 41,074 pleural mesothelioma patients diagnosed between 2004 and 2020:[1]
| Stage | Surgery Median OS [95% CI] | Chemotherapy Median OS [95% CI] | 2-Year Survival | 5-Year Survival |
|---|---|---|---|---|
| I | 19.2 [17.9–20.4] months | 15.5 [14.8–16.1] months | ~40% | ~15% |
| II | 19.2 [17.9–20.5] months | 16.1 [15.3–16.9] months | ~40% | ~14% |
| III | 18.9 [17–19.7] months | 15.5 [15–16.1] months | ~35% | ~11% |
| IV | 13.1 [12.4–13.9] months | 11.0 [10.7–11.4] months | ~20% | ~5% |
For the complete survival data across all stages and treatment modalities, see Survival_Statistics.
How Does Cell Type Affect Stage 3 Prognosis?
Histological cell type is consistently the most powerful predictor of mesothelioma survival, arguably more significant than stage itself. The NCDB data show:[4]
| Histology | Surgery Median OS | Chemotherapy Median OS | Immunotherapy Median OS |
|---|---|---|---|
| Epithelioid | 22.2 [21.1–23.3] months | 17.3 [16.7–17.8] months | 18.2 [16.5–19.8] months |
| Biphasic | 12.4 [11.3–13.5] months | 11.8 [11.1–12.4] months | 9.0 [7.3–10.7] months |
| Sarcomatoid | 6.4 [5.5–7.3] months | 6.6 [6.3–6.9] months | 15.1 [11.7–18.5] months |
Immunotherapy represents a paradigm shift for non-epithelioid histology: sarcomatoid patients receiving immunotherapy achieve a median survival of 15.1 months compared to just 6.4–6.6 months with surgery or chemotherapy alone. In the CheckMate 743 trial, non-epithelioid patients treated with nivolumab plus ipilimumab achieved a median survival of 16.9 months versus 8.8 months with chemotherapy (hazard ratio 0.46; 95% CI 0.31–0.70).[10]
These figures represent all-stage data and are not limited to Stage III patients. No published trial has reported Stage III-specific subgroup analyses for immunotherapy outcomes.
Does Stage IIIA Versus IIIB Make a Difference?
While no large studies have directly compared IIIA and IIIB survival in a dedicated analysis, the IASLC 9th edition staging proposal provides directional data using T-descriptor survival (which approximates the IIIA vs IIIB distinction):[9]
- Clinical T3 (the key descriptor in IIIA): median overall survival of approximately 21.1 months
- Clinical T4 (which defines IIIB): median overall survival of approximately 12.6 months
This 8.5-month difference underscores that Stage IIIA and IIIB represent meaningfully different levels of disease extent, with IIIA patients generally having better access to multimodal treatment options.
What Other Factors Affect Stage 3 Survival?
Within Stage III mesothelioma, several factors modify prognosis beyond stage and cell type:[5][11]
- Performance status (ECOG/Karnofsky): ECOG PS 0 patients have median survival approximately 3 times longer than PS 2 patients. Performance status is both prognostic and a key determinant of treatment eligibility.
- Sex: Female sex is consistently associated with approximately 15–35% lower mortality risk. The IASLC Staging Project found male sex carried a hazard ratio of 1.39 (95% CI 1.05–1.84; p=0.0202).[5]
- Age: Younger patients (<60–70 years) generally tolerate multimodal therapy better and have longer survival.
- Lymph node status: N0 patients have significantly better survival than N1 or N2 patients. Clinical N0 versus N1 median survival: 23.2 versus 18.5 months; pathological N0 versus N1: 33.8 versus 25.0 months.[9]
- Hematologic parameters: Thrombocytosis, leukocytosis, and anemia are associated with worse prognosis.[12]
How Has Treatment Changed Stage 3 Outcomes?
The treatment landscape for Stage 3 mesothelioma has undergone dramatic evolution over the past two decades. Three developments have reshaped the standard of care.
What Was the Pre-Immunotherapy Standard?
From 2004 until 2020, the standard first-line therapy for unresectable mesothelioma was pemetrexed plus cisplatin (or carboplatin), established by the landmark EMPHACIS trial. This combination achieved a median overall survival of 12.1 months versus 9.3 months for cisplatin alone (hazard ratio 0.77; p=0.020).[13] NCDB data show that population-level median survival improved from 8.97 months (2004–2007) to 12.1 months (2016–2019), reflecting a 35% relative increase as immunotherapy and multimodal therapy became more widely adopted.[1]
How Did Immunotherapy Transform Mesothelioma Treatment?
The CheckMate 743 trial — a phase III randomized study of 605 patients with unresectable pleural mesothelioma — demonstrated that nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) significantly improved overall survival compared to pemetrexed plus platinum chemotherapy:[10][14][2]
| Endpoint | Nivolumab + Ipilimumab | Chemotherapy | Hazard Ratio |
|---|---|---|---|
| Median OS | 18.1 months | 14.1 months | 0.74 (95% CI 0.60–0.91; p=0.0020) |
| 2-Year OS | 41% | 27% | — |
| 3-Year OS | 23% | 15% | — |
| 5-Year OS | 14% | 6% | 0.64 (treatment-switching adjusted) |
| Median DOR | 11.0 months | 6.7 months | — |
The 5-year update confirmed a durable and clinically meaningful survival benefit, with responses to immunotherapy maintained years after treatment completion — a pattern not seen with chemotherapy, where the 3-year progression-free survival was only 1%.[2]
For detailed information about the CheckMate 743 trial and other immunotherapy approaches, see Immunotherapy_for_Mesothelioma.
How Did MARS 2 Change the Role of Surgery?
The MARS 2 trial (2024) was a landmark phase III randomized trial that tested whether adding extended pleurectomy/decortication (ePD) to chemotherapy improved survival over chemotherapy alone in 335 patients:[6]
| Endpoint | Surgery + Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Median OS | 19.3 months | 24.8 months |
| Grade ≥3 SAEs | 318 events | 169 events |
| Cardiac complications | 3.01× higher | Reference |
| Respiratory complications | 2.62× higher | Reference |
Surgery was associated with worse survival and significantly more serious adverse events. This trial fundamentally challenged the role of cytoreductive surgery in mesothelioma, although it has limitations: the median follow-up was only 22.4 months, and patients were selected via a 2-cycle chemotherapy run-in period. Despite this, the results have led multiple guidelines to recommend against routine surgery or to limit surgical consideration to highly selected early-stage patients at experienced centers.[6]
For a comprehensive discussion of surgical approaches, see Mesothelioma_Surgery_Overview.
What Treatment Options Are Available for Stage 3 Patients?
Treatment for Stage 3 mesothelioma requires a multidisciplinary approach. The 2025 ASCO Guideline Update — the first since 2018 — provides the most current evidence-based treatment recommendations.[15]
What Is the Standard First-Line Treatment?
Three first-line regimens are now considered standard for unresectable pleural mesothelioma:[15]
| Regimen | Histology Preference | Key Supporting Trial |
|---|---|---|
| Nivolumab + ipilimumab | All histologies, especially non-epithelioid | CheckMate 743[10] |
| Pemetrexed + platinum (cisplatin or carboplatin) ± bevacizumab | Epithelioid | EMPHACIS / MAPS[13][16] |
| Pembrolizumab + pemetrexed + platinum | Epithelioid | IND227 / KEYNOTE-483[17] |
For patients with non-epithelioid histology (sarcomatoid or biphasic), immunotherapy is strongly preferred. The 2025 ASCO guidelines state that chemotherapy should be used only when immunotherapy is contraindicated in non-epithelioid patients.[15]
What About Tumor Treating Fields (TTFields)?
Tumor Treating Fields (TTFields) using the NovoTTF-100L device received FDA approval in 2019 for use with pemetrexed and platinum chemotherapy, based on the STELLAR phase II trial (n=80):[18]
- Median overall survival: 18.2 months (95% CI 12.1–25.8) versus 12.1 months historical control
- One-year survival: 62.2%
- Epithelioid subtype median OS: 21.2 months
Important context: The STELLAR trial compared TTFields plus chemotherapy against a historical control from 2003 — not against a randomized active comparator. The median OS of 18.2 months appears similar to CheckMate 743's 18.1 months, but these numbers cannot be directly compared because CheckMate 743 used a concurrent randomized chemotherapy arm (median 14.1 months), while STELLAR used a historical control from a different era. No head-to-head trial comparing TTFields plus chemotherapy against immunotherapy has been conducted.[18]
When Is Surgery Still Considered for Stage 3?
Following MARS 2, the role of surgery in Stage 3 mesothelioma is limited. However, surgery may still be discussed for highly selected Stage IIIA patients at experienced centers. Key considerations include:[6][19]
- Pleurectomy/decortication (P/D) is preferred over extrapleural pneumonectomy (EPP) when surgery is performed. A multi-institutional analysis of 663 patients demonstrated EPP carried a hazard ratio of 1.4 versus P/D (p<0.001), with 30-day mortality of 7% (EPP) versus 4% (P/D).
- Patient selection is critical: epithelioid histology, N0 nodal status, good performance status (ECOG 0–1), and feasibility of macroscopic complete resection are generally required
- The 2025 ASCO and NCCN guidelines restrict surgical consideration to select patients at high-volume centers
For the full discussion of EPP versus P/D and surgical decision-making, see Mesothelioma_Surgery_Overview and Extrapleural_Pneumonectomy.
What Happens When First-Line Treatment Stops Working?
The 2025 ASCO guideline establishes clear second-line recommendations based on which first-line therapy was received:[15]
After first-line immunotherapy (nivolumab + ipilimumab):
- Pemetrexed + platinum ± bevacizumab — a Japanese retrospective study (n=43) showed median OS of 17.1 months and 1-year OS of 62.8% when pemetrexed-platinum was used after immunotherapy failure[20]
After first-line chemotherapy:
- Gemcitabine + ramucirumab — The RAMES trial demonstrated median OS of 13.8 months versus 7.5 months for gemcitabine alone (HR 0.71)[21]
- Oral vinorelbine — The VIM trial showed median PFS of 4.2 versus 2.8 months (HR 0.59; p=0.0017)[22]
- Nivolumab ± ipilimumab (if not received first-line)
- Pemetrexed rechallenge (if good prior response and treatment-free interval)
Pemetrexed maintenance therapy is not recommended per the 2025 guidelines. Gemcitabine switch maintenance may be offered as a conditional recommendation.[15]
What Clinical Trials Are Open for Stage 3 Mesothelioma?
Clinical trials offer Stage 3 mesothelioma patients access to emerging therapies that may improve outcomes beyond current standard treatment. Several promising agents are under investigation.
What Is VT3989?
VT3989 is a first-in-class TEAD inhibitor developed by Vivace Therapeutics that targets the Hippo signaling pathway — frequently disrupted in mesothelioma through NF2 gene mutations. As of early 2026, VT3989 has received:[8]
- Orphan Drug Designation (July 2025) for treatment of mesothelioma
- Fast Track Designation (October 2025) for patients whose disease has progressed on prior immune checkpoint inhibitor therapy and platinum-based chemotherapy
In the Phase 1/2 trial (NCT04665206), among 22 mesothelioma patients treated at the optimized dose (100 mg once-daily, 2-weeks-on/2-weeks-off):[8]
- Objective response rate (ORR): 32% (7/22 partial responses)
- Disease control rate (DCR): 86% (19/22 achieved PR or stable disease)
- Median progression-free survival: 40 weeks (~10 months) — more than double the ~15-week benchmark for standard therapies in this population
A registrational Phase 3 trial is planned for the first half of 2026.
What Other Trials Are Available?
Several additional therapies are being investigated for mesothelioma patients, including those with Stage 3 disease:
- Mesothelin-targeted CAR-T cell therapy — Memorial Sloan Kettering's phase I trial showed median OS of 23.9 months when CAR-T cells were combined with pembrolizumab (n=18)[23]
- ADI-PEG 20 (arginine deprivation therapy) — ATOMIC trial targeting ASS1-deficient mesothelioma tumors (Phase II/III)
- TTFields + immunotherapy combinations — preclinical evidence suggests TTFields may upregulate PD-L1 and convert immunologically "cold" tumors to "hot," with combination trials ongoing[24]
- Pembrolizumab + pemetrexed + platinum followed by sequential second-line options (KEYNOTE-483)
Patients can search for currently enrolling mesothelioma trials at ClinicalTrials.gov. Eligibility varies by trial — most require adequate organ function and ECOG performance status 0–1. Many trials enroll patients with Stage III and IV disease.
Where Should Stage 3 Patients Seek Treatment?
The choice of treatment facility significantly affects outcomes for Stage 3 mesothelioma patients. Because mesothelioma is rare (approximately 3,000 new cases per year in the United States), most hospitals have limited experience with the disease.
Does Treatment Center Volume Affect Survival?
Yes. The most rigorous evidence comes from the NCDB volume–outcome analysis by Simone et al. (2018), which examined surgical outcomes across facilities of varying case volume:[7]
- High-volume facilities (90th percentile of surgical case volume): 90-day mortality 10.0% and median OS 18 months
- Lower-volume facilities: 90-day mortality 14.6% and median OS 15 months
A separate institutional series from the Lung Institute at Baylor College of Medicine found that treatment at academic centers was associated with better overall survival (HR 1.18 for nonacademic facilities) and that greater travel distance to a specialty center was paradoxically associated with improved survival (HR 0.92), likely reflecting patient selection for referral to high-volume programs.[1]
What Should Stage 3 Patients Look for in a Treatment Center?
Patients diagnosed with Stage 3 mesothelioma should seek evaluation at a center that offers:
- Multidisciplinary mesothelioma tumor board — with thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and pathologists experienced in mesothelioma
- Access to clinical trials — particularly emerging therapies like TEAD inhibitors and immunotherapy combinations
- High surgical case volume — if surgery is being considered, experience with pleurectomy/decortication is essential
- NCI-designated Comprehensive Cancer Center status or equivalent academic medical center designation
Major mesothelioma treatment programs include Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Mount Sinai/Tisch Cancer Center, MD Anderson Cancer Center, Moffitt Cancer Center, and the University of Pennsylvania/University of Maryland photodynamic therapy program, among others.[19]
For more information about treatment center selection, see Mesothelioma_Treatment_Centers.
Should Stage 3 Patients Get a Second Opinion?
A second opinion from a mesothelioma specialist is strongly recommended for any Stage 3 patient. Because mesothelioma is rare, many community oncologists may have limited experience with the disease. A specialist at a high-volume center may recommend different treatment approaches, identify clinical trial eligibility, or offer a more nuanced prognostic assessment based on substage, cell type, and molecular characteristics. Second opinions can often be conducted via telehealth or remote pathology review, and most insurance plans cover them.
What Legal Rights Do Stage 3 Patients Have?
Many patients with Stage 3 mesothelioma developed the disease due to occupational or environmental asbestos exposure. Several forms of financial compensation may be available. This section provides a general overview of options — it is not legal advice, and patients should consult with an attorney experienced in asbestos litigation.
What Compensation Options Exist?
- Asbestos trust funds — Over 60 bankruptcy trust funds hold approximately $30 billion in assets for asbestos claimants. Trust fund claims can often be resolved in months rather than years and do not require litigation.
- Personal injury lawsuits — Patients diagnosed with mesothelioma may file claims against manufacturers, employers, or property owners responsible for asbestos exposure. Mesothelioma lawsuits often settle for significant compensation due to the disease's strong causal link to asbestos.
- VA benefits for veterans — Mesothelioma is recognized as a service-connected condition for veterans with documented asbestos exposure during military service. VA disability compensation, healthcare, and Dependency and Indemnity Compensation (DIC) may be available.
- Workers' compensation — Separate from personal injury claims, workers' compensation may cover medical treatment and lost wages.
Why Is Timing Important for Stage 3 Patients?
Statutes of limitations set deadlines for filing legal claims. These deadlines vary by state and typically begin running from the date of diagnosis. Because Stage 3 represents an advanced disease with a limited prognosis, patients and their families should consult with an asbestos attorney promptly after diagnosis to preserve their legal rights. Some states have statutes of limitations as short as one year from diagnosis.
For a free evaluation of your legal options from experienced mesothelioma attorneys, visit mesotheliomalawyersnearme.com or call for a free case review.
Helpful resources:
Frequently Asked Questions
What Is the Life Expectancy for Stage 3 Mesothelioma?
The median life expectancy for Stage 3 pleural mesothelioma ranges from approximately 15.5 months with chemotherapy to 18.9 months with surgery plus chemotherapy, based on NCDB data from 41,074 patients (2004–2020).[1] However, individual life expectancy varies widely depending on cell type (epithelioid patients live roughly 2–3 times longer than sarcomatoid patients), performance status, age, and treatment received. Modern immunotherapy with nivolumab plus ipilimumab has achieved a 5-year overall survival rate of 14% across all stages in the CheckMate 743 trial.[2]
Can Stage 3 Mesothelioma Be Cured?
Mesothelioma is generally considered incurable at any stage, including Stage 3. However, long-term survival is achievable for a subset of patients. In the CheckMate 743 trial, 14% of patients treated with immunotherapy were alive at 5 years, and some maintained ongoing responses at the time of follow-up.[2] In surgical series, selected patients with epithelioid histology and complete resection have achieved survival beyond 5 years.[19] The term "functional cure" is sometimes used when patients achieve durable disease control lasting many years.
What Are the Treatment Options for Stage 3 Mesothelioma?
First-line options include nivolumab plus ipilimumab (immunotherapy), pemetrexed plus platinum chemotherapy with or without bevacizumab, pembrolizumab plus chemotherapy, and TTFields with chemotherapy. Surgery (pleurectomy/decortication) may be considered for select Stage IIIA patients at experienced centers, though the MARS 2 trial showed surgery did not improve survival over chemotherapy alone.[6] Second-line options include gemcitabine with ramucirumab, oral vinorelbine, or pemetrexed rechallenge. Clinical trials testing novel agents such as the TEAD inhibitor VT3989 are also available.[8]
Is Stage 3 Mesothelioma Operable?
Stage 3 mesothelioma may be operable in carefully selected cases, particularly Stage IIIA patients with epithelioid histology, no mediastinal lymph node involvement (N0 or N1), and good performance status (ECOG 0–1). Stage IIIB disease (T4 tumors invading the chest wall diffusely, spine, great vessels, or contralateral pleura) is generally considered unresectable. However, following the MARS 2 trial, the benefit of surgery even in earlier-stage disease is debated. Surgical decisions should be made at high-volume mesothelioma centers with multidisciplinary tumor boards.[6][19]
How Long Do Stage 3 Mesothelioma Patients Live With Immunotherapy?
No published trial has reported Stage III-specific immunotherapy survival data. Across all stages in CheckMate 743, patients treated with nivolumab plus ipilimumab achieved a median overall survival of 18.1 months, with 41% alive at 2 years, 23% at 3 years, and 14% at 5 years.[10][2] Non-epithelioid patients derived particularly large benefit, with a hazard ratio of 0.46 compared to chemotherapy.[10] Because Stage III patients are routinely enrolled in immunotherapy trials and generally have adequate performance status, these all-stage figures likely approximate Stage III outcomes.
What Is Stage 3A vs Stage 3B Mesothelioma?
Stage 3A (IIIA) indicates locally advanced disease that is potentially resectable: T3 tumors (invading endothoracic fascia, mediastinal fat, or solitary chest wall focus) with or without ipsilateral lymph node involvement (N0–N2), or lower T-stage tumors with N1–N2 nodal disease. Stage 3B (IIIB) indicates technically unresectable local disease: T4 tumors that have invaded the chest wall diffusely, peritoneum, contralateral pleura, mediastinal organs, brachial plexus, or spine, regardless of nodal status. IIIA patients generally have more treatment options and better prognosis than IIIB patients.[3]
Is Stage 3 Mesothelioma Terminal?
Stage 3 mesothelioma is a serious and life-threatening diagnosis, but "terminal" implies no treatment options exist — which is not the case. Effective treatments including immunotherapy, chemotherapy, TTFields, and in select cases surgery can extend survival significantly. Five-year survival of 14% with modern immunotherapy means that a meaningful minority of patients achieve long-term disease control.[2] Quality of life is also an important consideration: the CheckMate 743 trial showed that immunotherapy maintained or improved patient-reported quality of life compared to chemotherapy, with delay in time to definitive deterioration (HR 0.52).[14]
What Is the Best Treatment for Stage 3 Pleural Mesothelioma?
The best treatment depends on cell type, performance status, and patient preference. For most patients with unresectable Stage 3 pleural mesothelioma, nivolumab plus ipilimumab is the recommended first-line treatment, particularly for non-epithelioid histology. For epithelioid patients, pemetrexed plus platinum chemotherapy (with or without bevacizumab or pembrolizumab) is an alternative. TTFields plus chemotherapy is FDA-approved and may be considered. The optimal treatment should be determined by a multidisciplinary team at an experienced mesothelioma center.[15][10]
Can Stage 3 Mesothelioma Patients Qualify for Clinical Trials?
Yes. Most mesothelioma clinical trials enroll patients with Stage III and Stage IV disease. Eligibility typically requires adequate organ function, ECOG performance status 0–1, and measurable disease on imaging. Many trials are specifically designed for patients whose disease has progressed on prior immunotherapy and chemotherapy. The VT3989 Phase 1/2 trial, for example, enrolled 135 mesothelioma patients including those previously treated with immune checkpoint inhibitors and platinum-based chemotherapy.[8] Patients can search for trials at ClinicalTrials.gov or ask their oncologist about available options.
What Financial Compensation Is Available for Stage 3 Mesothelioma Patients?
Patients with Stage 3 mesothelioma caused by asbestos exposure may be eligible for compensation through several channels: asbestos bankruptcy trust funds (over $30 billion in assets across 60+ trusts), personal injury lawsuits against asbestos manufacturers and employers, VA disability benefits for veterans with service-connected exposure, workers' compensation claims, and Social Security Disability Insurance (SSDI). Because statutes of limitations apply and vary by state, patients should consult with an experienced asbestos attorney soon after diagnosis.
See Also
- Survival_Statistics — Overall survival statistics across all mesothelioma stages and types
- Mesothelioma_Diagnosis_and_Staging — Complete overview of staging systems including TNM 8th and 9th editions
- Immunotherapy_for_Mesothelioma — Detailed CheckMate 743 trial data and immunotherapy options
- Mesothelioma_Treatment_Options — Comprehensive treatment overview
- Mesothelioma_Surgery_Overview — Surgical approaches including P/D vs EPP decision-making
- Peritoneal_Mesothelioma — Peritoneal mesothelioma staging and outcomes (CRS-HIPEC)
- Mesothelioma_Prognosis — General prognosis and prognostic factors
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Bou-Samra P, Chang A, Azari F, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023;12(18):18526–18540. PMID: 37700498. DOI: 10.1002/cam4.6440.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Scherpereel A, Baas P, Nowak AK, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol. 2026. DOI: 10.1200/JCO-25-01328.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Nowak AK, Chansky K, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2018;13(12):1738–1749. PMID: 30266660. DOI: 10.1016/j.jtho.2018.09.002.
- ↑ 4.0 4.1 Bou-Samra P, Chang A, Azari F, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023;12(18):18526–18540. PMID: 37700498.
- ↑ 5.0 5.1 5.2 5.3 Wolf AS, Rosenthal A, Giroux DJ, et al. The IASLC Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors. J Thorac Oncol. 2023;18(11):1548–1563. PMID: 37567386. DOI: 10.1016/j.jtho.2023.08.005.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(5):349–360. PMID: 38608687. DOI: 10.1016/s2213-2600(24)00119-x.
- ↑ 7.0 7.1 Simone CB, Cengel KA, Glatstein E. Palliative care and the surgical treatment of mesothelioma: volume–outcome relationship in the National Cancer Database. Lung Cancer. 2018;122:7–13. PMID: 29748018. DOI: 10.1016/j.lungcan.2018.05.009.
- ↑ 8.0 8.1 8.2 8.3 8.4 Yap TA, Lakhani NJ, Engstrom LD, et al. First-in-class TEAD inhibitor VT3989 in patients with advanced solid tumors including mesothelioma. Nature Medicine. 2025. DOI: 10.1038/s41591-025-03271-9.
- ↑ 9.0 9.1 9.2 Gill RR, Nowak AK, Giroux D, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming 9th Edition. J Thorac Oncol. 2024;19(6):899–913. DOI: 10.1016/j.jtho.2024.03.007.
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. PMID: 33485464. DOI: 10.1016/S0140-6736(20)32714-8.
- ↑ Linton A, Cheng YY, Griggs K, et al. An RCT of two doses of pemetrexed for malignant pleural mesothelioma. Br J Cancer. 2014;111(7):1321–1328. PMID: 25187000. DOI: 10.1038/bjc.2014.478.
- ↑ Waller DA, Edwards JG, Rajesh PB. Prognostic factors in malignant mesothelioma. Eur J Cardiothorac Surg. 2000;18(2):195–199. PMID: 10950889.
- ↑ 13.0 13.1 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. PMID: 12860938. DOI: 10.1200/JCO.2003.11.136.
- ↑ 14.0 14.1 Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–499. PMID: 35091043. DOI: 10.1016/j.annonc.2022.01.074.
- ↑ 15.0 15.1 15.2 15.3 15.4 15.5 ASCO Guideline Update: Systemic Therapy for Unresectable Malignant Pleural Mesothelioma. J Clin Oncol. 2025. DOI: 10.1200/JCO-24-02425.
- ↑ Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414. DOI: 10.1016/S0140-6736(15)01311-2.
- ↑ Chu Q, Piccirillo MG, Greillier L, et al. IND227 phase III study of cisplatin/pemetrexed with or without pembrolizumab. J Clin Oncol. 2023;41(17 Suppl):LBA8505. DOI: 10.1200/jco.2023.41.17_suppl.lba8505.
- ↑ 18.0 18.1 Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Final results of Phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma. Ann Oncol. 2019;30(Suppl 5):v602. DOI: 10.1093/ANNONC/MDZ069.
- ↑ 19.0 19.1 19.2 19.3 Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–626. PMID: 18329481. DOI: 10.1016/j.jtcvs.2007.10.003.
- ↑ Pemetrexed-platinum as second-line after nivolumab-ipilimumab for unresectable malignant pleural mesothelioma. Lung Cancer. 2025. PMID: 40819510.
- ↑ Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22(10):1438–1447. PMID: 34499874. DOI: 10.1016/S1470-2045(21)00404-6.
- ↑ Fennell DA, et al. VIM: Vinorelbine in mesothelioma. ASCO 2021 Abstract 8507.
- ↑ Adusumilli PS, et al. Mesothelin-targeted CAR T-cell therapy for malignant pleural mesothelioma. Cancer Discovery. 2021. PMC: PMC8563385.
- ↑ Sarkari A, Steer C, Lou E, et al. Treatment with tumor-treating fields suppresses intercellular tunneling nanotube formation and upregulates immuno-oncologic biomarkers in malignant mesothelioma. eLife. 2023;12:e85383. DOI: 10.7554/eLife.85383. PMC: PMC10642963.
Diagnosed with mesothelioma? Get help from experienced mesothelioma lawyers who can evaluate your case and explain your legal options at no cost.
Find a Mesothelioma Lawyer | Asbestos Trust Fund Guide | Mesothelioma Lawyers Near Me